An N-methylguanidine-bridged nucleic acid (GuNA [NMe]), a guanidine-bridged nucleic acid (GuNA) bearing a methyl substituent at the bridge, was successfully synthesised and incorporated into oligonucleotides. By employing an acetyl protecting group, GuNA[NMe]-modified oligonucleotides bearing acid-sensitive purine nucleobases were successfully prepared. 
Introduction
The clinical application of antisense oligonucleotides (ASOs) is becoming a reality as several ASO drugs have been approved by the U.S. Food and Drug Administration (FDA) . 1 The ASOs used in clinical applications and/or in in vitro/in vivo experiments are generally chemically modified DNA/RNA oligos, where the modifications play an important role in enhancing the biophysical and pharmacokinetic properties of the ASOs (e.g. the enzymatic stability against nuclease-mediated degradation, duplex-forming ability towards target RNAs, and cellular/tissue distribution). 2 One of the most widely used chemical modifications is the phosphorothioate (PS) backbone modification, which greatly increases the enzymatic stability and cellular/ tissue distribution. Other important modifications are sugar modifications, such as 2′-fluoro (2′-F), 2′-O-methoxyethyl (MOE), and 2′,4′-bridged nucleic acid/locked nucleic acid (2′,4′-BNA/LNA, Fig. 1 ). These three modifications impart strong binding affinity towards target RNAs and a certain degree of enzymatic stability. The covalent attachment of cationic functional groups, such as guanidino and amino groups, is also a reliable modification to enhance the enzymatic stability, duplex-forming ability, and cellular uptake. 3 We have recently designed and synthesised guanidinebridged nucleic acid (GuNA, Fig. 1 ), bearing a positively charged 2′-4′ bridge structure. 4 The GuNA-modified oligonucleotides (ONs) were found to exhibit extremely high binding affinity towards the complementary single-stranded RNA (ssRNA) and DNA (ssDNA) and show far superior enzymatic stability compared to their 2′,4′-BNA/LNA-modified counterparts. These data clearly demonstrate that GuNA is a promising approach for the modification of therapeutic ASOs. A wide variety of 2′,4′-BNA/LNA analogues currently exist, and ONs/ASOs modified with such analogues have been rigorously evaluated in vitro and in vivo.
2,5 Interestingly, recent studies showed that even a simple methyl substitution at the 2′-4′ bridge has a large impact on the pharmacokinetics as well as biophysical properties. For example, ONs/ASOs modified with an amido-bridged nucleic acid bearing a methyl group at the 2′-4′ amide bridge (AmNA[NMe]) exhibit higher (Table 1) . At first, the guanidination of 1 was performed using N,N′-bis(tert-butoxycarbonyl)-N,S-dimethylisothiourea (2a) 10 in the presence of silver(I) triflate 11 and triethylamine to yield 3a, but this resulted in no reaction even at 60°C (entries 1 and 2). In contrast, N′-Boc-N-methylisothiourea 2b successfully afforded the guanidinated product 3b in 88% yield (entry 3). The trace amounts of 3c obtained from N-Boc-N-methylisothiourea 2c (entry 4) indicated that this guanidination reaction proceeded via a carbodiimide mechanism. 12 The 3′-hydroxyl group of product 3b was then phosphitylated to afford N-Boc-protected GuNA[NMe]-T phosphoramidite 4 (Scheme 1). The ON synthesis was performed in an automated DNA synthesiser following the standard phosphoramidite protocol, except for a prolonged coupling time (16 min) for the incorporation of 4 into the ONs. After oligomer elongation, the Boc protecting groups were removed by treatment with TMSOTf and 2,6-lutidine in CH 2 Cl 2 9 (rt, 24 h), and the resulting ONs were cleaved from the solid support using aqueous ammonia (rt, 4 h; then 60°C, 8 h). Finally, the GuNA[NMe]-modified T10-mers (ON1-ON5) were successfully isolated, as shown in Table 2 . However, the preparation of ON6 containing acid-sensitive purine nucleobases 13 was unsuccessful. These results show a sequence limitation for ON synthesis with N-Boc-protected phosphoramidite 4.
Approach using an Ac-protecting group for the synthesis of GuNA[NMe]-modified ONs
To overcome the above limitation, we decided to synthesise an N-Ac-protected GuNA[NMe]-T phosphoramidite, expecting that the alternative Ac group could be removed under aqueous ammonia conditions. The N-Ac-protected phosphoramidite 7 was prepared in the same way as N-Boc-protected phosphoramidite 4, as shown in Scheme 2. Briefly, 2′-amino-LNA 1 was guanidinated with N′-acetyl-N-methylisothiourea 5 to afford 6, which was then converted into the desired phosphoramidite 7. Phosphoramidite 7 was then incorporated into ONs, and the deprotection of the Ac group was subsequently conducted in a 7 N ammonia methanol solution/28% aqueous ammonia (1 : 1, 60°C, 8 h). As expected, the cleavage of ONs from the solid support followed by Ac deprotection was successfully achieved in a one-pot process. However, the above reaction was Oligonucleotide sequence 
Scheme 2 Reagents and conditions:
slow and produced a considerable amount of by-products, arising from the replacement of the methylamino group with an amino group, i.e. GuNA (Fig. 2 , ca. GuNA[NMe]/GuNA = 3 : 1). We found that switching the reagent to 7 N ammonia methanol solution/40% aqueous methylamine (1 : 1, rt, 4 h; then 60°C, 10 h) 14 efficiently minimised the conversion to
GuNA and furnished the desired unprotected ONs in good yield (Table 3) . Notably, ON6 containing purine nucleobases was successfully obtained by this method.
Duplex-forming ability of GuNA[NMe]-modified ONs
The thermal stability of the duplexes formed by the GuNA [NMe]-modified ONs (ON1-ON6) and the complementary ssRNA or ssDNA was then evaluated by UV melting experiments, and the obtained melting temperatures (T m ) are summarised in Table 4 that methyl substitution at the guanidine bridge has no practical impact on the duplex-forming ability. Therefore, further functionalisation of GuNAs with no loss of their duplexforming ability may be possible by introducing various substituents (e.g. fluorescent groups and tissue-targeting groups) at the guanidine bridge.
Enzymatic stability of GuNA[NMe]-modified ONs
The stability of the GuNA[NMe]-modified ONs against enzymatic degradation was then evaluated. T10-mers with the 3′-terminal thymidine replaced with GuNA[NMe]-T, GuNA-T, LNA, or 5′-PS-linked thymidine (5′-PS-T) were incubated with 3′-exonuclease (Crotalus adamanteus venom phosphodiesterase, CAVP) in Tris-HCl buffer ( pH 8.0) at 37°C, and the percentage of intact ONs was analysed by HPLC over time. As shown in Fig. 3 , the natural T10-mer (ON8) was degraded within 5 min and the LNA-modified T10-mer (ON15) was degraded within 10 min. In contrast, the GuNA[NMe]-and GuNA-modified congeners (ON7 and ON16, respectively) showed dramatically improved enzymatic stability. ON17 with the well-established PS modification exhibited similar stability to that of ON7 and ON16, revealing that GuNA and GuNA[NMe] are both valuable modifications to enhance the enzymatic stability. The strong resistance of ON7 against nuclease activity possibly arises mainly from the positive charge of the guanidine moiety, since the methyl substitution seems to contribute little to the resistance (ON7 vs. ON16).
Conclusions
GuNA 
Experimental
All moisture-sensitive reactions were carried out in well-dried glassware under an N 2 atmosphere. 1 H spectra were recorded at 300, 400, or 500 MHz. 13 C NMR spectra were recorded at 76, 100, or 126 MHz. 31 P NMR spectra were recorded at 162 or 202 MHz. Chemical shifts (δ) are expressed in ppm relative to internal tetramethylsilane (0.00 ppm) or residual CHCl 3 (7.26 ppm) in the 1 H NMR spectra, internal tetramethylsilane (0.00 ppm) or chloroform-d 1 (δ = 77.0 ppm) in the 13 C NMR spectra, and 85% H 3 PO 4 (δ = 0.00 ppm) in the 31 P NMR spectra. MALDI-TOF mass spectra of all new compounds were obtained on a SpiralTOF JMS-S3000 instrument. For column chromatography, PSQ-60B or PSQ-100B silica gel was used. The progress of the reactions was monitored by analytical thin layer chromatography (TLC) on glass plates (TLC silica gel 60 F 254 ) and the products were visualised by UV light.
To a mixture of 1 (451 mg, 0.79 mmol) and N′-tert-butoxycarbonyl-N,S-dimethylisothiourea (2b) (258 mg, 1.3 mmol) in anhydrous THF (8.0 mL), silver triflate (410 mg, 1.6 mmol) and triethylamine (0.45 mL, 3.2 mmol) were added at 0°C. The resulting mixture was then stirred overnight at room temperature. After the completion of the reaction, water was added and the product was extracted with CHCl 3 . 3215, 3067, 2977, 2836, 1692, 1606, 1509, 1447, 1390, 1365, 1273, 1254, 1176, 1149, 1038 12.6, 28.2, 30.2, 54.6, 55.2, 59.3, 63.5, 70.1, 78.5, 86.3, 86.5, 88.8, 110.8, 113.2, 127.0, 128.0, 130.0, 130.0, 134.3, 135.2, 135.5, 144.3, 150.5, 158.6, 161.2, 161.4, 164 
To a solution of 3b (423 mg, 0.58 mmol) in anhydrous CH 2 Cl 2 (6.0 mL), N,N-diisopropylethylamine (240 µL, 1.4 mmol) and 2-cyanoethyl-N,N-diisopropylchlorophosphoramidite (200 µL, 0.87 mmol) were added, and the resulting mixture was stirred for 6 h at room temperature. After the completion of the reaction, sat. aq. NaHCO 3 was added and the product was extracted with CH 2 Cl 2 . The organic phase was washed with water and brine, dried over Na 2 SO 4 , and concentrated under reduced pressure. The product was purified by column chromatography (n-hexane/AcOEt = 1 : 3) to afford 4b (411 mg, 76%) as a white solid. 
To a mixture of 1 (2.0 g, 3.5 mmol) and N′-acetyl-N,S-dimethylisothiourea (5) (560 mg, 3.9 mmol) in anhydrous THF (35 mL), silver triflate (1.4 g, 5.4 mmol) and N,N-diisopropylethylamine (0.80 mL, 5.2 mmol) were added at 0°C. The resulting mixture was then stirred overnight at room temperature. After the completion of the reaction, AcOEt (40 mL) and sat. aq. NH 4 Cl (15 mL) were added, and the mixture was filtered. The filtrate was extracted with AcOEt, washed with water and brine, dried over Na 2 SO 4 , and concentrated under reduced pressure. The product was purified by column chromatography (CHCl 3 / MeOH = 5 : 1) to afford 6 (2.0 g, 85%) as a white solid.
[α] 6.83 (2H, d , J = 9.2 Hz), 6.83 (2H, d, m), 7.57 (1H, s), 8.74 (1H, br) ppm; 13 C NMR (CDCl 3 ): δ 12. 4, 25.9, 29.3, 53.7, 55.2, 59.1, 63.4, 69.8, 85.8, 86.7, 88.5, 111.0, 113.2, 127.0, 127.9, 128.2, 130.0, 130.1, 134.2, 135.1, 135.5, 144.1, 150.3, 158.6, 161.2, 163.9 
To a solution of 6 (2.0 g, 3.0 mmol) in anhydrous CH 2 Cl 2 (37 mL), N,N-diisopropylethylamine (2.1 mL, 12 mmol) and 2-cyanoethyl-N,N-diisopropylchlorophosphoramidite (1.3 mL, 6.0 mmol) were added, and the resulting mixture was stirred for 6 h at room temperature. After the completion of the reaction, sat. aq. NaHCO 3 was added and the product was extracted with CHCl 3 . The organic phase was washed with water and brine, dried over Na 2 SO 4 , and concentrated under reduced pressure. The product was purified by column chromatography (CHCl 3 / MeOH = 12 : 1) to afford 7 (2.2 g, 84%) as a white solid. 6.82-6.87 (4H, m), 7.23-7.36 (7H, m), 7.42-7.47 (2H, m) Oligonucleotide synthesis using N-Boc-protected GuNA[NMe]-T phosphoramidite
The synthesis at 0.2 µmol scale of oligonucleotides modified with GuNA[NMe] was performed using an nS-8 oligonucleotide synthesiser (GeneDesign, Inc.) according to the standard phosphoramidite protocol with 0.5 M 5-ethylthio-1H-tetrazole as the activator. Custom Primer Support™ T 40s (GE Healthcare Life Sciences) was used as the solid support. The amidite solutions were dehydrated by using Molecular Sieves Pack 3A (Wako). The standard synthesis cycle was used for the assembly of the reagents and synthesis of the oligonucleotides, except that the coupling time was extended to 16 min. The synthesis was carried out in "trityl on" mode. The Boc protecting groups were removed using 1.0 M TMSOTf and 1.25 M 2,6-lutidine in CH 2 Cl 2 (rt, 24 h). The resulting oligonucleotides were cleaved from the solid support by treatment with concentrated ammonium hydroxide (rt, 4 h; then 60°C, 8 h).
Oligonucleotide synthesis using N-Ac-protected GuNA[NMe]-T phosphoramidite
The synthesis at 0.2 µmol scale of oligonucleotides modified with GuNA[NMe] was performed using an nS-8 oligonucleotide synthesiser (GeneDesign, Inc.) according to the standard phosphoramidite protocol with 0.5 M 5-ethylthio-1H-tetrazole as the activator. Custom Primer Support™ T 40s (GE Healthcare Life Sciences) or NittoPhase® UnyLinker™ 50 (Kinovate Life Sciences) was used as the solid support. The amidite solutions were dehydrated by using Molecular Sieves Pack 3A (Wako). The standard synthesis cycle was used for the assembly of the reagents and synthesis of the oligonucleotides, except that the coupling time was extended to 16 min. The synthesis was carried out in "trityl on" mode. The oligonucleotides were cleaved from the solid support by treatment with a mixture of 7 N ammonia in methanol and 40% aq. methylamine (50 : 50) (rt, 4 h; then 60°C, 10 h).
Oligonucleotide purification and characterisation
The oligonucleotides were initially purified with a Waters SepPak Plus C18 Cartridge. The oligonucleotides were further purified by reverse-phase HPLC with Waters XBridge™ C18 (4.6 × 50 mm analytical and 10 × 50 mm preparative) columns with a linear gradient of MeCN in 0.1 M triethylammonium acetate ( pH 7.0). The oligonucleotides were analysed for purity by reverse-phase HPLC and characterised by MALDI-TOF mass spectrometry (SpiralTOF JMS-S3000).
UV melting experiments and melting profile
UV melting experiments were carried out on a Shimadzu UV-1650 spectrophotometer equipped with a T m analysis accessory. Equimolecular amounts of the target RNA or DNA strand and oligonucleotide were dissolved in 10 mM sodium phosphate buffer at pH 7.2 containing 100 mM NaCl to give a final strand concentration of 4 µM. The samples were annealed by heating at 95°C, followed by slow cooling to room temperature. The melting profile was recorded at 260 nm from 0 to 90°C at a scan rate of 0.5°C min −1 . The T m values, i.e. the temperatures of half-dissociation of the formed duplexes, were determined by the first derivative of the melting curve.
Nuclease resistance evaluation
The synthesis and purification of the LNA-, GuNA-, or 5′-PS-Tmodified oligonucleotides (ON15-ON17) were conducted by Gene Design Inc. (Osaka, Japan). The 5′-PS-T-modified oligonucleotide was prepared as a stereoisomeric mixture. The sample solutions were prepared by dissolving 0.75 µmol of oligonucleotides in 50 mM Tris-HCl buffer ( pH 8.0) containing 10 mM MgCl 2 . To each sample solution, 0.25 µg CAVP was added and the cleavage reaction was carried out at 37°C. Aliquots of each reaction mixture were removed at timed intervals and heated to 90°C for 2 min to deactivate the nuclease, which were then analysed by reverse-phase HPLC to evaluate the amount of intact oligonucleotides remaining. The percentage of intact oligonucleotides in each sample was calculated and plotted against the digestion time to obtain a degradation curve.
